52 results
8-K
EX-99.1
NKGN
NKGen Biotech Inc
11 Apr 24
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
8:05am
focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced … on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics. NKGen is headquartered in Santa
8-K
EX-99.1
NKGN
NKGen Biotech Inc
28 Dec 23
Other Events
4:14pm
of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced the dosing of the first patient in its Phase 1/2a trial … biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK NK cell therapies. NKGen
8-K
EX-99.1
7qzvtr obof27
27 Dec 23
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
4:02pm
8-K
EX-99.1
bsgksiulvg fv
14 Nov 23
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
4:36pm
8-K
EX-99.4
gra 14m06pgcpz95i
5 Oct 23
Index to Financial Statements
5:12pm
8-K
EX-99.2
60m hm0l7mwun
5 Oct 23
Index to Financial Statements
5:12pm
8-K
EX-99.1
8g39v
5 Oct 23
Index to Financial Statements
5:12pm
425
EX-99.1
jyk 846h2b29k
22 Sep 23
Business combination disclosure
9:27am
8-K
EX-99.1
0dwo0p
22 Sep 23
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting
9:26am
424B3
zzh6147
21 Sep 23
Prospectus supplement
7:31pm
425
EX-99.1
xywzm1
14 Sep 23
Business combination disclosure
9:31am
8-K
EX-99.1
tyih6fix6r9 y6
14 Sep 23
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting
9:30am
425
EX-99.1
wmfch6rto th6a4
11 Sep 23
Business combination disclosure
11:30am